Mei Zhen Wu

US Patent:

58436359, Dec 1, 1998

Filed:

Feb 27, 1995

Appl. No.:

8/395149

Inventors:

Stuart F. Schlossman - Newton MA
Mei X. Wu - Cambridge MA

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 170
G01N 33564
C07K 1600

US Classification:

435 5

Abstract:

Methods for interfering with antigen presenting cell-mediated priming of resting peripheral blood T lymphocytes to undergo activation induced cell death ("apoptosis") by inhibiting an interaction between a membrane associated molecule ("an APC apoptotic ligand") present on stimulated antigen presenting cells ("APC") and a counter-receptor that is present on T lymphocytes are disclosed. The antigen presenting cells are preferably from the monocyte/macrophage cell line or are dendritic cells. Also disclosed are methods of screening for inhibitors of APC-mediated priming of T lymphocytes to undergo apoptosis and methods and agents for detecting, identifying and characterizing an APC apoptotic ligand. Inhibitors identified by the screening method of the invention are used to reduce the T lymphocyte depletion associated with HIV infection and thereby mitigate the severe immunodeficiency associated with AIDS by interfering with the association between HIV-infected antigen presenting cells, especially monocytes and macrophages, and T cells.

US Patent:

20220362153, Nov 17, 2022

Filed:

Oct 6, 2020

Appl. No.:

17/767140

Inventors:

- Boston MA, US
Mei Xiong Wu - Lexington MA, US

International Classification:

A61K 9/127
A61K 39/145
A61K 39/39
A61P 31/16

Abstract:

Compositions and methods comprising Pulmonary Surfactant (PS)-biomimetic nanoparticles are disclosed. Specifically, the disclosure is related to a composition comprising a nanoparticle with an average size of 200-400 nm, including a plurality of pulmonary surfactant biomimetic molecules, wherein the nanoparticle is negatively charged; and one or more cargo molecules that are enveloped by the nanoparticle, wherein the cargo molecule has a molecular weight up to 1200 Da.

US Patent:

20230080345, Mar 16, 2023

Filed:

Mar 5, 2021

Appl. No.:

17/909287

Inventors:

- Boston MA, US
Mei X. Wu - Boston MA, US

International Classification:

A61N 5/06

Abstract:

Low level light (LLL) can be used to restore a subject's gut microbiota to a state of health. The LLL can be applied directly to the subject's abdomen and/or back, or the LLL can be applied to a feces sample obtained from the subject, which is subsequently administered back to the subject. The subject may be suffering from guy dysbiosis resulting from a variety of different types of bodily stress, such as chemotherapy or radiation therapy.

US Patent:

20180008838, Jan 11, 2018

Filed:

Jan 22, 2016

Appl. No.:

15/545039

Inventors:

- Boston MA, US
Mei X. Wu - Boston MA, US

International Classification:

A61N 5/06
A61B 5/00
A61B 5/145
A61M 37/00
A61B 5/15
A61N 5/067

Abstract:

The present disclosure relates generally to devices, systems, and methods for diagnosis and treatment via laser-treated skin and, more particularly, to devices, systems, and methods for inducing leakage or rupture of one or more blood vessels comprising the dermis for various diagnostic and therapeutic applications. Other aspects of the present disclosure can include methods for detecting one or more target analytes in a dermis of a subject, methods for facilitating skin-to-blood delivery of agent in a subject, and methods for collecting a fluid sample from the dermis of a subject.

US Patent:

20160038591, Feb 11, 2016

Filed:

Mar 13, 2014

Appl. No.:

14/776296

Inventors:

Mei X. WU - Lexington MA, US
Rex R. ANDERSON - Boston MA, US

International Classification:

A61K 41/00
A61N 5/06
A61M 37/00
A61K 39/39
A61K 39/145

Abstract:

A method and an system for vaccinating a mammalian subject. The method includes the steps of: arranging a source of electromagnetic radiation proximate to a target zone of skin of the mammalian subject; controlling the source of electromagnetic radiation to deliver a dose of electromagnetic radiation to the target zone determined to create one or more thermally-denatured zones in the target zone; and intradermally injecting a vaccine within the target zone to vaccinate the mammalian subject. The system for vaccinating a subject may include an electromagnetic radiation source configured to be arranged proximate to a target zone on an exterior of the subject; a user control configured to selectively cause the electromagnetic radiation source to deliver a dose of electromagnetic radiation toward the target zone to create one or more thermally-denatured zones in the target zone; and a vaccine-delivery system configured to deliver a vaccine to the target zone.